![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | No longer recruiting |
Unique ID issued by UMIN | UMIN000018480 |
Receipt No. | R000021362 |
Scientific Title | Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial |
Date of disclosure of the study information | 2015/07/31 |
Last modified on | 2020/08/01 |
Basic information | ||
Public title | Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial | |
Acronym | Japan Human Atrial Natriuretic Peptide for Lung Cancer Surgery (JANP study) | |
Scientific Title | Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial | |
Scientific Title:Acronym | Japan Human Atrial Natriuretic Peptide for Lung Cancer Surgery (JANP study) | |
Region |
|
Condition | ||
Condition | non-small cell lung cancer | |
Classification by specialty |
|
|
Classification by malignancy | Malignancy | |
Genomic information | YES |
Objectives | |
Narrative objectives1 | To investigate whether human atrial natriuretic peptide (hANP) can reduce the incidence of postoperative cancer recurrence in patients with completely resected non-small cell lung cancer. |
Basic objectives2 | Safety,Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | Confirmatory |
Trial characteristics_2 | Explanatory |
Developmental phase | Phase II,III |
Assessment | |
Primary outcomes | Two-year relapse free survival after lung cancer surgery |
Key secondary outcomes | 1. five-year relapse free survival after lung cancer surgery
2. Over all survival (5 years after surgery) 3. The ratio of the patients who completed the treatment 4. The incidence of postoperative complications |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | Individual |
Blinding | Open -no one is blinded |
Control | Active |
Stratification | NO |
Dynamic allocation | YES |
Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
Blocking | NO |
Concealment | Central registration |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | A: Lung cancer surgery with hANP treatment [Patients in the hANP group receive human ANP (0.025 microgram/kg/min for 3 days), which is started more than two hours before surgery] | |
Interventions/Control_2 | B: Surgery alone | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | Preoperative criteria
1. Non-small cell lung cancer is suspected. 2. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is more than 0.25. 3. It's possible to perfom the complete resection including mediastinal lymph node dissection. 4. Patient without simultaneous or metachronous (within the past 5 years) double cancers. 5. Aged more than 20 years 6. Performance status of 0-2. 7. Sufficient organ functions. 8. All patients gave written informed consent |
|||
Key exclusion criteria | 1. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is less than 0.25.
2. Patient with active the other concurrent malignant diseases. 3. Women during pregnancy or breast-feeding. 4. Psychosis. 5. Systemic steroids or immunosuppressive agents medication. 6. Uncontrollable infectious disease, autoimmune disease, or the other severe comorbidities. 7. History of right ventricular infarction. 8. Severe hypotension 9. Other conditions judged ineligible by physician |
|||
Target sample size | 500 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | National Cerebral and Cardiovascular Center Research Institute/Osaka University Graduate School of Medicine | ||||||
Division name | Biochemistry/General Thoracic Surgery | ||||||
Zip code | 565-8565 | ||||||
Address | 5-7-1, Fujishiro-dai, Suita-city, Osaka 565-8565, Japan/2-2 (L5), Yamadaoka, Suita-City, Osaka 565-0871, Japan | ||||||
TEL | 06-6833-5012 | ||||||
kangawa@ri.ncvc.go.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | National Cerebral and Cardiovascular Center Research Institute/Osaka University Hospital | ||||||
Division name | Biochemistry/General Thoracic Surgery | ||||||
Zip code | 565-8565 | ||||||
Address | 5-7-1, Fujishiro-dai, Suita-city, Osaka, Japan/2-2 (L5), Yamadaoka, Suita-City, Osaka, Japan | ||||||
TEL | 06-6833-5012 | ||||||
Homepage URL | |||||||
nojiri@ri.ncvc.go.jp |
Sponsor | |
Institute | National Cerebral and Cardiovascular Center |
Institute | |
Department |
Funding Source | |
Organization | Shionogi & Co., Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization | Japan |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Osaka University Hospital |
Address | Osaka, Japan/2-2 (L5), Yamadaoka, Suita-City, Osaka, Japan |
Tel | 06-6833-5012 |
nojiri@ri.ncvc.go.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions | 大阪大学医学部附属病院(大阪府)
大阪府立成人病センター(大阪府) 国立病院機構刀根山病院(大阪府) 大阪府立呼吸器・アレルギー医療センター(大阪府) 北海道大学病院(北海道) 山形大学医学部附属病院(山形県) 山形県立中央病院(山形県) 東京大学医学部附属病院(東京都) 神戸大学医学部附属病院(兵庫県) 国立がん研究センター東病院(千葉県) |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | 332 |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | No longer recruiting | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry |
|
||||||
Date trial data considered complete |
|
||||||
Date analysis concluded |
|
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021362 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |